M
Mark S. Kaminski
Researcher at University of Michigan
Publications - 181
Citations - 12308
Mark S. Kaminski is an academic researcher from University of Michigan. The author has contributed to research in topics: Tositumomab & Radioimmunotherapy. The author has an hindex of 53, co-authored 175 publications receiving 11334 citations. Previous affiliations of Mark S. Kaminski include Memorial Sloan Kettering Cancer Center & Medical College of Wisconsin.
Papers
More filters
Journal ArticleDOI
131I-tositumomab therapy as initial treatment for follicular lymphoma.
Mark S. Kaminski,Melissa Tuck,Judith Estes,Arne Kolstad,Charles W. Ross,Kenneth R. Zasadny,Denise Regan,Paul V. Kison,Susan J. Fisher,Stewart M. Kroll,Richard L. Wahl +10 more
TL;DR: A single one-week course of 131I-tositumomab therapy as initial treatment can induce prolonged clinical and molecular remissions in patients with advanced follicular lymphoma.
Journal ArticleDOI
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou,Laurie H. Sehn,Alfred Rademaker,Leo I. Gordon,Ann S. LaCasce,Allison Crosby-Thompson,Ann Vanderplas,Andrew D. Zelenetz,Gregory A. Abel,Maria Alma Rodriguez,Auayporn Nademanee,Mark S. Kaminski,Myron S. Czuczman,Michael Millenson,Joyce C. Niland,Randy D. Gascoyne,Joseph M. Connors,Jonathan W. Friedberg,Jane N. Winter +18 more
TL;DR: The NCCN-IPI is easy to apply and more powerful than the IPI for predicting survival in the rituximab era and demonstrated enhanced discrimination for both low- and high-risk patients.
Journal ArticleDOI
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Mark S. Kaminski,Kenneth R. Zasadny,Isaac R. Francis,Adam W. Milik,Charles W. Ross,Scott D. Moon,Shelley M. Crawford,Jeanne M. Burgess,Neil A. Petry,Gregory Butchko,Stephan D. Glenn,Richard L. Wahl +11 more
TL;DR: Radioimmunotherapy with 131I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B- cell lymphomas in whom primary chemotherapy had failed is a promising new treatment for lymphoma.
Journal ArticleDOI
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Mark S. Kaminski,Andrew D. Zelenetz,Oliver W. Press,Mansoor N. Saleh,John P. Leonard,L. Fehrenbacher,T. A. Lister,R. J. Stagg,George F. Tidmarsh,Stewart Kroll,Richard L. Wahl,Susan J. Knox,J. M. Vose +12 more
TL;DR: A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with chemotherapy-refractory, low-grade, or transformed low- grade non-Hodgkin's lymphoma and had an acceptable safety profile.
Journal ArticleDOI
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
Mark S. Kaminski,Judith Estes,Kenneth R. Zasadny,Isaac R. Francis,Charles W. Ross,Melissa Tuck,Denise Regan,Susan J. Fisher,Jeanne Gutierrez,Stewart Kroll,Robert Stagg,George F. Tidmarsh,Richard L. Wahl +12 more
TL;DR: A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL.